acyl-CoA synthetase medium chain family member 5Genealiases: []
Q-omics provides the consensus-scored ACSM5 profile across patient tissues and cancer cell-line models. ACSM5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ACSM5 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, ACSM5 RNA expression shows 23,163 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where ACSM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSM5 survival associations across molecular data types. ACSM5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSM5 RNA expression–survival associations across cancer types. High ACSM5 expression shows unfavorable associations in UVM, but favorable associations in KIRC, SKCM, ACC, LUAD and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ACSM5 RNA expression.
This table summarizes ACSM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACSM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSM5 shows lower tumor expression in COAD, KICH, THCA, LUAD and LIHC and higher tumor expression in KIRC. The KIRC box plot shows higher ACSM5 RNA expression in tumor versus normal tissue (log2 FC = +1.805, t-test p < 0.001).
This table shows molecular features associated with ACSM5 in patient tissues and cancer cell lines. In patient samples, ACSM5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
